New gene therapy for wet age-related macular degeneration is on the horizon
Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration have, so far, gone at least six months without the need for continued injections to control a disease that typically requires treatment every four to six weeks.